Form 4 for NKTR NEKTAR THERAPEUTICS
Accepted 2025-12-23 00:00:00 ET · period of report 2025-12-22 · accession 0001193125-25-331187 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-23 | 2025-12-22 | NKTR | ROBIN HOWARD W | Pres, CEO, Dir | A - Grant | $0.00 | +21.7K | 75.9K | +40% | $0 |
| D | 2025-12-23 | 2025-12-22 | NKTR | ROBIN HOWARD W | Pres, CEO, Dir | A - Grant | $0.00 | +86.7K | 86.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-22 | A | A | 21,667 | $0.00 | 75,912 | D | — | — | (F1) Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs vest over four years from the date of grant (December 22, 2025) in substaintially equal quarterly installments based on continued service. |
| 2 | Derivative | Stock Option | 2025-12-22 | A | A | 86,667 | $0.00 | 86,667 | D | $43.48 · — to 2033-12-21 | 86,667 Common Stock | (F2) Stock options vest over four years from the date of grant, (December 22, 2025) in substantially equal monthly installments based on continued service. |